<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8129">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03001115</url>
  </required_header>
  <id_info>
    <org_study_id>P16-052</org_study_id>
    <nct_id>NCT03001115</nct_id>
  </id_info>
  <brief_title>Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects</brief_title>
  <acronym>HS rPMS</acronym>
  <official_title>Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Patients Under the &quot;New-Drug Re-examination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis
      Suppurativa (HS) participants in normal medical practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessing adverse events</measure>
    <time_frame>Up to 70 days following the last administration of Humira®</time_frame>
    <description>Adverse event information is collected to assess prevalence of safety.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hidradenitis Suppurativa Clinical Response (HiSCR)</measure>
    <time_frame>Week 0 (baseline), Week 12, and Week 24</time_frame>
    <description>The HiSCR measure is designed to assess treatment response in a binary manner, rather than being a continuous or ordinal scale. It includes a count of the total number of abscesses and inflammatory nodules (ANs), as well as recording the number of sinuses draining purulent fluid present in an individual. Treatment responders are defined as those who achieve at least a 50% reduction in ANs, with no increase in the number of abscesses or draining sinuses, relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Week 0 (baseline), Week 12, and Week 24</time_frame>
    <description>DLQI will be collected to evaluate effectiveness of adalimumab. DLQI has 10 quality of life domains scored from 0 (no effect) to thirty (very large effect).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <arm_group>
    <arm_group_label>Participants with Hidradenitis suppurativa (HS)</arm_group_label>
    <description>Participants with HS treated with adalimumab (HUMIRA®) in routine clinical practice.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Hidradenitis suppurativa (HS) participants who have been prescribed Adalimumab by the
        treating investigator as per approved label in Korea will be enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant who are eligible to be treated with adalimumab for HS in accordance with
             the approved Korean label

          -  Participant must provide written authorization form to use their personal health data
             prior to the participating in the study.

        Exclusion Criteria:

          -  Participant who are contraindications to adalimumab as listed on the approved Korean
             label.

          -  Participant who is participating on other clinical trials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eunjung Gu</last_name>
    <role>Study Director</role>
    <affiliation>Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SuKyung Kim</last_name>
    <phone>+82-2-3429-9235</phone>
    <email>sukyung.kim@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EunJung Gu</last_name>
    <phone>+82-2-3429-9399</phone>
    <email>eunjung.gu@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dong-A University Hospital /ID# 162931</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital /ID# 162930</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital /ID# 162932</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital /ID# 163243</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital /ID# 162922</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital /ID# 162935</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System /ID# 162933</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Medical Center /ID# 162936</name>
      <address>
        <city>Seoul</city>
        <zip>04564</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hangyang University Medical Center /ID# 162929</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center /ID# 162927</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center /ID# 162925</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital /ID# 162924</name>
      <address>
        <city>Seoul</city>
        <zip>06058</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center /ID# 162934</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital of the Catholic University /ID# 162923</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangnam Sacred Heart hospital /ID# 162926</name>
      <address>
        <city>Seoul</city>
        <zip>07441</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital /ID# 162928</name>
      <address>
        <city>Seoul</city>
        <zip>07985</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Abbott South Korea /ID# 153577</name>
      <address>
        <city>Seoul</city>
        <zip>135-846</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 24, 2017</lastchanged_date>
  <firstreceived_date>December 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Korean participants</keyword>
  <keyword>Hidradenitis Suppurativa</keyword>
  <keyword>Safety</keyword>
  <keyword>Adalimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hidradenitis</mesh_term>
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
